14 assets in Clear Cell Adenocarcinoma

Therapeutic assets addressing Clear Cell Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Adriamycin Clear Cell Adenocarcinoma	Yonsei University	P2	CCC (53)
Dostarlimab Clear Cell Adenocarcinoma	Yonsei University	P2	CCC (53)
Lorigerlimab Clear Cell Adenocarcinoma	MacroGenics	P2	CCC (53)
NKT2152 Clear Cell Adenocarcinoma	NiKang Therapeutics, Inc.	P1/2	CCC (48)
Fludarabine Clear Cell Adenocarcinoma	M.D. Anderson Cancer Center	P1	CC (46)
Cyclophosphamide Clear Cell Adenocarcinoma	M.D. Anderson Cancer Center	P1	CC (43)
Dexasone Clear Cell Adenocarcinoma	M.D. Anderson Cancer Center	P1	CC (43)
Tgfbr-2 Ko Cd70 Car Nk Clear Cell Adenocarcinoma	M.D. Anderson Cancer Center	P1	CC (43)
Vudalimab Clear Cell Adenocarcinoma	Xencor, Inc.	P2	CC (43)
13C-Fructose Clear Cell Adenocarcinoma	University of Texas Southwestern Medical Center	N/A	D (30)
Acetic-1-13C Acid Clear Cell Adenocarcinoma	University of Texas Southwestern Medical Center	N/A	D (30)
Glucose, Anhydrous Clear Cell Adenocarcinoma	University of Texas Southwestern Medical Center	N/A	D (30)
Glutamine Clear Cell Adenocarcinoma	University of Texas Southwestern Medical Center	N/A	D (30)
Lactate Clear Cell Adenocarcinoma	University of Texas Southwestern Medical Center	N/A	D (30)